307 related articles for article (PubMed ID: 32134464)
1. Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
Petito LC; García-Albéniz X; Logan RW; Howlader N; Mariotto AB; Dahabreh IJ; Hernán MA
JAMA Netw Open; 2020 Mar; 3(3):e200452. PubMed ID: 32134464
[TBL] [Abstract][Full Text] [Related]
2. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
[TBL] [Abstract][Full Text] [Related]
3. Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer.
Boyne DJ; Cheung WY; Hilsden RJ; Sajobi TT; Batra A; Friedenreich CM; Brenner DR
JAMA Netw Open; 2021 Mar; 4(3):e213587. PubMed ID: 33783516
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database.
Shin S; Park CM; Kwon H; Lee KH
BMC Cancer; 2016 Jul; 16():443. PubMed ID: 27400734
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer.
Goel S; Negassa A; Acuna-Villaorduna A
JAMA Netw Open; 2021 Dec; 4(12):e2136378. PubMed ID: 34910154
[TBL] [Abstract][Full Text] [Related]
7. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
[TBL] [Abstract][Full Text] [Related]
8. Treatment and Survival of Small-bowel Adenocarcinoma in the United States: A Comparison With Colon Cancer.
Young JI; Mongoue-Tchokote S; Wieghard N; Mori M; Vaccaro GM; Sheppard BC; Tsikitis VL
Dis Colon Rectum; 2016 Apr; 59(4):306-15. PubMed ID: 26953989
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
[TBL] [Abstract][Full Text] [Related]
10. Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Fulop DJ; Zylberberg HM; Wu YL; Aronson A; Labiner AJ; Wisnivesky J; Cohen DJ; Sigel KM; Lucas AL
JAMA Netw Open; 2023 Mar; 6(3):e234254. PubMed ID: 36951863
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens.
Kizilbash SH; Ward KC; Liang JJ; Jaiyesimi I; Lipscomb J
Int J Clin Pract; 2014 May; 68(5):578-89. PubMed ID: 24472057
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data.
Weiss JM; Schumacher J; Allen GO; Neuman H; Lange EO; Loconte NK; Greenberg CC; Smith MA
Ann Surg Oncol; 2014 Jun; 21(6):1781-91. PubMed ID: 24643898
[TBL] [Abstract][Full Text] [Related]
14. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
Raphael MJ; Raskin W; Habbous S; Tai X; Beca J; Dai WF; Arias J; Forbes L; Gavura S; Biagi JJ; Earle CC; Chan KKW
JAMA Netw Open; 2021 Nov; 4(11):e2133388. PubMed ID: 34779846
[TBL] [Abstract][Full Text] [Related]
15. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Hammel P; Huguet F; van Laethem JL; Goldstein D; Glimelius B; Artru P; Borbath I; Bouché O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C;
JAMA; 2016 May; 315(17):1844-53. PubMed ID: 27139057
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
Hsiao FY; Mullins CD; Onukwugha E; Pandya N; Hanna N
J Am Geriatr Soc; 2011 Sep; 59(9):1717-23. PubMed ID: 21831168
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Chemotherapy Regimens in Prolonging Survival for Two Large Population-Based Cohorts of Elderly Adults with Breast and Colon Cancer in 1992-2009.
Du XL; Zhang Y; Parikh RC; Lairson DR; Cai Y
J Am Geriatr Soc; 2015 Aug; 63(8):1570-82. PubMed ID: 26200214
[TBL] [Abstract][Full Text] [Related]
18. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
Maurel J; Sánchez-Cabús S; Laquente B; Gaba L; Visa L; Fabregat J; Povés I; Roselló S; Díaz-Beveridge R; Martín-Richard M; Rodriguez J; Sabater L; Conill C; Cambray M; Reig A; Ayuso JR; Valls C; Ferrández A; Bombí JA; Ginés A; García-Albéniz X; Fernández-Cruz L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):935-943. PubMed ID: 30225601
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
Wang JP; Wu CY; Yeh YC; Shyr YM; Wu YY; Kuo CY; Hung YP; Chen MH; Lee WP; Luo JC; Chao Y; Li CP
Oncotarget; 2015 Jul; 6(20):18162-73. PubMed ID: 26046796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
